In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends.

Area of Science:

• Medical Diagnostics
• Infectious Disease Research
• Biotechnology

Background:

• Significant advancements have been made in in vitro diagnostic (IVD) assays for coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
• Current molecular diagnostic methods, primarily real-time reverse transcriptase polymerase chain reaction (RT-PCR), have seen reduced assay durations, with some point-of-care (POC) molecular assays providing results in as little as 5 minutes.

Discussion:

• A variety of serology immunoassays (IAs), including automated chemiluminescent IA (CLIA), manual ELISA, and rapid lateral flow IA (LFIA), complement molecular assays.
• These immunoassays detect immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies, indicating a person's immune response to SARS-CoV-2 infection.

Key Insights:

• Many COVID-19 molecular diagnostic tests have received emergency use authorization (EUA) from the United States Food and Drug Administration (FDA) and Conformité Européenne (CE) marking.
• The development of rapid IVD assays is crucial for timely diagnosis and management of COVID-19.
• The performance of all IVD assays must be rigorously evaluated for reliable clinical diagnosis.

Outlook:

• Ongoing research and technological advancements are expected to yield new POC IVD assays for COVID-19 in the near future.
• Further innovation in complementary technologies will enhance the capabilities and accessibility of diagnostic testing.
• Continued focus on assay validation will ensure the clinical utility and accuracy of emerging diagnostic solutions.